Adaptive CEO Robins sells 124,998 ADPT shares

Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported a planned stock sale.

Accepted by SEC EDGAR 02/04/2026 - 07:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported a planned stock sale. On February 2, 2026, he sold 124,998 shares of Common Stock at a weighted average price of $18.44 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.

After this sale, Robins beneficially owned 2,459,245 shares of Adaptive Biotechnologies Common Stock in direct form.

Insider Trade Summary

Net Seller: 124,998 shares

Net Sell 1 txn

Insider ROBINS CHAD M

Role CEO and Chairman

Sold 124,998 shs ($2.30M)

Type	Security	Shares	Price	Value
Sale	Common Stock	124,998	$18.44	$2.30M

Holdings After Transaction: Common Stock — 2,459,245 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
2. F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADPT CEO Chad M. Robins report?

Chad M. Robins reported selling 124,998 shares of Adaptive Biotechnologies Common Stock. The sale occurred on February 2, 2026 at a weighted average price of $18.44 per share, as disclosed in his Form 4 insider trading report.

How many ADPT shares does Chad M. Robins own after this Form 4 sale?

After the reported sale, Chad M. Robins beneficially owned 2,459,245 shares of Adaptive Biotechnologies Common Stock. The filing states these shares are held directly, reflecting his remaining equity position following the February 2, 2026 transaction.

Was Chad M. Robins’ ADPT stock sale under a Rule 10b5-1 plan?

Yes. The filing explains the transactions were effected under a Rule 10b5-1 trading plan adopted by Chad M. Robins on August 11, 2025. Such plans pre-establish trading instructions to systematically sell shares over time.

What price did Chad M. Robins receive for his ADPT share sale?

The Form 4 reports a weighted average sale price of $18.44 per share. Footnotes clarify the shares were sold in multiple trades at prices ranging from $18.16 to $18.88, with full price breakdowns available on request.

What role does Chad M. Robins hold at Adaptive Biotechnologies (ADPT)?

Chad M. Robins is identified as both a Director and the CEO and Chairman of Adaptive Biotechnologies. His dual leadership and board roles are disclosed in the Form 4 alongside details of his February 2, 2026 stock sale.

Is the Chad M. Robins ADPT stock sale a direct or indirect holding change?

The filing classifies the transaction as a direct ownership change. After selling 124,998 shares on February 2, 2026, Chad M. Robins directly held 2,459,245 shares of Adaptive Biotechnologies Common Stock, with no indirect ownership nature specified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS CHAD M

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		124,998	D	$18.44(2)	2,459,245	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.